<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985942</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-007-501</org_study_id>
    <nct_id>NCT04985942</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group,&#xD;
      fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the&#xD;
      Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an&#xD;
      inadequate response to ongoing ADT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in three periods:&#xD;
&#xD;
        -  Screening Period (up to 2 weeks) during which patient eligibility will be assessed;&#xD;
&#xD;
        -  Double-blind Treatment Period (6 weeks) in which all patients will be randomized to&#xD;
           receive placebo or lumateperone 42mg/day in 1:1 ratio.&#xD;
&#xD;
        -  Safety Follow-up Period (1 week) in which all patients will return to the clinic for a&#xD;
           safety follow-up visit approximately one week after the last dose of study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale</measure>
    <time_frame>Day 43</time_frame>
    <description>The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Severity</measure>
    <time_frame>Day 43</time_frame>
    <description>The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Lumateperone 42 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumateperone</intervention_name>
    <description>Lumateperone 42 mg capsules administered orally, once daily.</description>
    <arm_group_label>Lumateperone 42 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching capsules administered orally, once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients between the ages of 18 and 65 years, inclusive;&#xD;
&#xD;
          2. Meets DSM-5 criteria for MDD as confirmed by using the MINI and meets all of the&#xD;
             following criteria:&#xD;
&#xD;
               1. The start of the current major depressive episode (MDE) is at least 8 weeks but&#xD;
                  not more than 18 months prior to Screening;&#xD;
&#xD;
               2. Has at least moderate severity of illness based on rater-administered MADRS total&#xD;
                  score ≥ 24 at Screening and at Baseline;&#xD;
&#xD;
               3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening&#xD;
                  and at Baseline;&#xD;
&#xD;
               4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item&#xD;
                  (QIDS-SR-16) score ≥14 at Screening and at Baseline;&#xD;
&#xD;
               5. and the current MDE is causing clinically significant distress or impairment in&#xD;
                  social, occupational, or other important areas of functioning.&#xD;
&#xD;
          3. Currently having an inadequate response to ADT (less than 50% improvement) as&#xD;
             confirmed by the Investigator and taking at least the minimum effective dose (per&#xD;
             package insert) of one of the following antidepressants as monotherapy treatment for&#xD;
             at least 6 weeks duration:&#xD;
&#xD;
               1. citalopram/escitalopram&#xD;
&#xD;
               2. fluoxetine&#xD;
&#xD;
               3. paroxetine&#xD;
&#xD;
               4. sertraline&#xD;
&#xD;
               5. duloxetine&#xD;
&#xD;
               6. levomilnacipran/milnacipran (if locally approved for MDD)&#xD;
&#xD;
               7. venlafaxine/desvenlafaxine&#xD;
&#xD;
               8. buproprion&#xD;
&#xD;
               9. vilazodone&#xD;
&#xD;
              10. vortioxetine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than&#xD;
             MDD, including:&#xD;
&#xD;
               1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other&#xD;
                  psychotic disorder;&#xD;
&#xD;
               2. Bipolar Disorder;&#xD;
&#xD;
          2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than&#xD;
             MDD including:&#xD;
&#xD;
               1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder;&#xD;
                  Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary&#xD;
                  diagnoses.&#xD;
&#xD;
               2. Eating disorder;&#xD;
&#xD;
               3. Substance use disorders (excluding nicotine);&#xD;
&#xD;
               4. Personality disorder of sufficient severity to have a major impact on the&#xD;
                  patient's psychiatric status;&#xD;
&#xD;
               5. Within 12 months of Screening, has had any other psychiatric condition (other&#xD;
                  than MDD) that has been the main focus of treatment;&#xD;
&#xD;
          3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening&#xD;
             and Baseline;&#xD;
&#xD;
          4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between&#xD;
             Screening and Baseline;&#xD;
&#xD;
          5. In the opinion of the Investigator, the patient has a significant risk for suicidal&#xD;
             behavior during participation in the study or:&#xD;
&#xD;
               1. At Screening, the patient scores &quot;yes&quot; on Suicidal Ideation Items 4 or 5 of the&#xD;
                  Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to&#xD;
                  Screening, or at Baseline, the patient scores &quot;yes&quot; on Suicidal Ideation Items 4&#xD;
                  or 5 since the Screening Visit;&#xD;
&#xD;
               2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior&#xD;
                  to Screening;&#xD;
&#xD;
               3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal&#xD;
                  Thoughts), or&#xD;
&#xD;
               4. The patient is considered to be in imminent danger to him/herself or others.&#xD;
&#xD;
          6. The patient has a first MDE at age 60 years or older.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ITI Clinical Trials</last_name>
    <phone>646 440-9333</phone>
    <email>ITCIClinicalTrials@itci-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78737</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjunctive MDD Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

